Lee N. Newcomer

TL;DR: The high costs associated with cancer care have created a difficult situation for patients and the oncologists who care for them and will require greater understanding of all the risks and benefits of various treatment options as well as the consequences of specific choices.

TL;DR: The value framework has been constructed as a conceptual model that incorporates the elements of clinical benefit, toxicity, and symptom palliation as derived from a comparative clinical trial and combines these elements into a score termed the net health benefit (NHB).

TL;DR: A multidisciplinary task force consisting of oncologists, nurses, pharmacists, and payor representatives to discuss the impact of the increasing use of oral chemotherapy was convened.

TL;DR: Oncology costs increase in the last 6 MBD largely because of increased IP costs, whereas OP costs decrease, according to a retrospective claims database affiliated with OptumInsight.

TL;DR: Recommendations are offered designed to serve as a roadmap to break this vicious cycle of undervaluation and call for a national dialogue, as changes in regulation, reimbursement, investment, peer review, and guidelines development require the participation of all stakeholders.